Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2018-1593

2. Registrant Information.

Registrant Reference Number: SC2087390

Registrant Name (Full Legal Name no abbreviations): Dow AgroSciences Canada Inc.

Address: 215-2nd Street SW, Suite 2400

City: Calgary

Prov / State: AB

Country: Canada

Postal Code: T2P 1M4

3. Select the appropriate subform(s) for the incident.

Human

4. Date registrant was first informed of the incident.

04-AUG-17

5. Location of incident.

Country: CANADA

Prov / State: BRITISH COLUMBIA

6. Date incident was first observed.

Unknown

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.

Active(s)

---

PMRA Registration No. 29334      PMRA Submission No.       EPA Registration No.

Product Name: GARLON RTU HERBICIDE

• Active Ingredient(s)
  • TRICLOPYR

---

7. b) Type of formulation.

Application Information

8. Product was applied?

Yes

9. Application Rate.

Unknown

10. Site pesticide was applied to (select all that apply).

Site: Personal use / Usage personnel

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding application.

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?

Unknown

Subform II: Human Incident Report (A separate form for each person affected)

1. Source of Report.

Data Subject

2. Demographic information of data subject

Sex: Male

Age: >19 <=64 yrs / >19 <=64 ans

3. List all symptoms, using the selections below.

System

• Skin
  • Symptom - Irritated skin
  • Symptom - Itchy skin
  • Symptom - Rash

4. How long did the symptoms last?

Unknown / Inconnu

5. Was medical treatment provided? Provide details in question 13.

Unknown

6. a) Was the person hospitalized?

No

6. b) For how long?

Unknown

7. Exposure scenario

Occupational

8. How did exposure occur? (Select all that apply)

Application

What was the activity? Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding the activity

9. If the exposure occured during application or re-entry, what protective clothing was worn? (select all that apply)

Unknown

10. Route(s) of exposure.

Unknown

11. What was the length of exposure?

>1 wk <=1 mo / > 1 sem < = 1 mois

12. Time between exposure and onset of symptoms.

<=30 min / <=30 min

13. Provide any additional details about the incident (eg. description of the frequency and severity of the symptoms, type of medical treatment, results from medical tests, outcome of the incident, amount of pesticide exposed to, etc.)

8/4/2017 Caller began using the product at his workplace around 2 weeks ago. Caller applies product with a backpack sprayer. Caller believes product may have contacted his skin, but states that he wears protective gear while using the product and has never noticed the product soaking through his clothing. Caller developed a rash on his arms and back, which he describes as itching and irritating, almost immediately after he stated using the product.

To be determined by Registrant

14. Severity classification.

Minor

15. Provide supplemental information here.

There does not appear to be any direct evidence of a defined exposure taking place. The reporter's description of exposure is speculative. The differential diagnosis for a skin condition of this nature would include multiple potential etiologies. Skin patch testing would be required before labeling this product as the causative agent. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.